Selumetinib in Children with Inoperable Plexiform Neurofibromas

BACKGROUND: No approved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1. METHODS: We conducted an open-label, phase 2 trial of selumetinib to determine the objective response rate among patients with plexiform neurofibromas and to assess clinical bene...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Gross, Andrea M., Wolters, Pamela L., Dombi, Eva, Baldwin, Andrea, Whitcomb, Patricia, Fisher, Michael J., Weiss, Brian, Kim, AeRang, Bornhorst, Miriam, Shah, Amish C., Martin, Staci, Roderick, Marie C., Pichard, Dominique C., Carbonell, Amanda, Paul, Scott M., Therrien, Janet, Kapustina, Oxana, Heisey, Kara, Clapp, D. Wade, Zhang, Chi, Peer, Cody J., Figg, William D., Smith, Malcolm, Glod, John, Blakeley, Jaishri O., Steinberg, Seth M., Venzon, David J., Doyle, L. Austin, Widemann, Brigitte C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7305659/
https://ncbi.nlm.nih.gov/pubmed/32187457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1912735
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados